Revolve Wealth Partners’s Edwards Lifesciences EW Stock Holding History

Revolve Wealth Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$206K	Buy	+2,276	New	+$191K	0.02%	343
2023 Q3	–	Sell	-2,305	Closed	-$217K	–	152
2023 Q2	$217K	Buy	+2,305	New	+$200K	0.05%	134
2022 Q4	–	Sell	-2,559	Closed	-$211K	–	149
2022 Q3	$211K	Sell	2,559 -233	-8%	-$22.4K	0.07%	118
2022 Q2	$265K	Buy	2,792 +96	+4%	+$9.94K	0.09%	102
2022 Q1	$317K	Sell	2,696 -7	-0.3%	-$785	0.09%	99
2021 Q4	$350K	Buy	+2,703	New	+$315K	0.1%	98

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Revolve Wealth Partners's EW Position: Q2 2026 in Review

Revolve Wealth Partners opened a new position in Edwards Lifesciences (EW) in Q2 2026: 2,276 shares worth $206K. The stake represents 0.02% of the portfolio and ranks #343 among its holdings. This is a return to the name: Revolve Wealth Partners previously reported a position in EW as recently as Q2 2023.

Revolve Wealth Partners first reported a position in EW in Q4 2021 and has held it in 6 quarters since. The position peaked at $350K in Q4 2021. 1,330 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Revolve Wealth Partners held 2,276 shares of Edwards Lifesciences worth $206K as of Q2 2026.
Edwards Lifesciences was a new Revolve Wealth Partners position in Q2 2026.
Edwards Lifesciences made up 0.02% of Revolve Wealth Partners's portfolio in Q2 2026, its #343 holding.
Revolve Wealth Partners first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 6 quarters since.
Revolve Wealth Partners's Edwards Lifesciences position peaked at $350K in Q4 2021.
1,330 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Revolve Wealth Partners's 13F filing for Q2 2026, filed 9 Jul 2026.